Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Pfizer's Phase 2 study of ponsegromab met its primary endpoint, showing a 5.6% mean increase in body weight at the highest dose compared to placebo in cancer cachexia patients. Ponsegromab was generally safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass. Registration-enabling studies are planned to start in 2025.